Tycho

Tycho is a techbio organization combining deep drug discovery industry knowledge with advanced technology expertise to unlock novel discovery opportunities.

Led by experienced industry executives, tycho develop AI drug discovery projects and strategic fractional roles and advisory services designed to bridge the gap between deep science and cutting-edge technology.

Problem: Designing novel peptides for complex membrane targets is traditionally slow and costly.

Solution: The Tycho Framework blends advanced AI models with human expertise to design peptides in weeks, drastically slashing costs.

Market: Therapeutics, radiotherapy, rare diseases.

Model: Project spin-offs, AI design contracts, and advisory.

Team: Pharma execs, AI experts, and KOLs (A. Bresciani, R. De Francesco).

Funding: Pre-seed/seed funds will drive our lead antiviral project through in vivo PoC and pre-IND.